



ALLIANCE
F O R U M
F O U N D A T I O N

Organization in Special Consultative Status
with the UN Economic and Social Council

www.allianceforum.org/en

2018

World Alliance Forum
in San Francisco

*Healthcare Game Changers:
Innovations in Science, Policy & Business
for Healthy Aging*

Golden Gate Club
November 15 & 16, 2018

Organized by:

Alliance Forum Foundation

Government of Japan

www.wafsf.org

Table of Contents

	Page
<i>Greetings</i>	3
<i>Program</i>	6
<i>Speakers' Biography</i>	10
<i>Sponsors</i>	32
<i>About Alliance Forum Foundation</i>	42

ALLIANCE FORUM FOUNDATION

*Organization in Special Consultative Status
with the UN Economic and Social Council*

Greetings from George Hara

Chairman of the Board, Alliance Forum Foundation

I would like to extend my heartfelt welcome and appreciation to everyone for your participation in the 2018 World Alliance Forum San Francisco (WAFSF).

Let me share with you my overarching purpose of chairing WAFSF. My goal is *to enable every person to live a healthy life until his/her last moment*. There are three important factors to achieve this goal: (1) innovations in technology that enables a full, healthy life even after a serious illness or injury, (2) innovations in policy that encourage scientific and technological advances and accelerate access to them, and (3) an ecosystem where technology and policy innovations thrive sustainably.

By bringing together the best minds in different fields both within and outside healthcare from the United States, Japan, and other countries around the world, WAFSF continues to support and accelerate each of these three factors through exciting discussion, networking and **collaboration. It's in this spirit that WAFSF is organized every year.**

Finally, I would also like to take this opportunity to express my gratitude to the distinguished speakers for helping to design the future of healthy aging. Equally, our deepest appreciation goes to our sponsors who every year help to make this unique conference possible.

Sincerely,



Ambassador George Hara
Chairman of the Board,
Alliance Forum Foundation

(Organization in Special Consultative Status with the UN ECOSOC)

Special Advisor to the Cabinet Office of the Prime Minister of Japan



Greetings

Greetings from the Consul General of Japan

Consul General of Japan in San Francisco

Congratulations to the World Alliance Forum on hosting its 6th annual event in San Francisco. The World Alliance Forum has the ability to assemble global experts in one locale, creating the **unique opportunity for meaningful dialogue and collaboration. This year's continuing theme, "Healthcare Game Changers: Innovation in Science, Policy & Business for Healthy Aging," remains to be a topic that is applicable across all borders, as we focus on "healthy aging" in our continued efforts to tackle related challenges.**

Japan has already become "the world's No.1 super-aged society". In order to examine the ground design of policies to realize future economic and social systems in this position, the Abe administration has established the "Council for Designing a 100-Year Life Society" to set up discussions for a "lifelong society," where all citizens including seniors can continue to play an active role.

To realize such a society, it is necessary to thoroughly advance health and preventive care investments for every generation. This contributes directly to the revitalization of our local society and the economy, not only by minimizing future medical costs and nursing care expenses, but also by allowing our citizens to enjoy fulfilling, long lives.

In addition, it is necessary to create a number of reliable local health care services that are easily accessible. In order to solve these issues in Japan and in other countries in the near future, cooperation between global experts in numerous fields such as academia, industry, government, is of the utmost importance.

I commend the efforts of the World Alliance Forum for its direct contributions to the Japanese **government's national goals and to the advancement of new technologies in regenerative medicine, gene therapy, cancer immunotherapy, and digital health.** It is my sincere hope that new fruitful connections will be made throughout the next few days, and further contribute to US-Japan collaborations in the field of advanced healthcare technologies.



Consul General Tomochika Uyama
Consul General of Japan in San Francisco



Event Summary

2018 World Alliance Forum in San Francisco

Title:	Healthcare Game Changers: Innovations in Science, Policy & Business for Healthy Aging
Date & Time:	Thursday, November 15, 2018 9:00 am – 5:35 pm (Reception: 5:35 pm – 6:30 pm) Friday, November 16, 2018 9:00 am – 5:20 pm (Reception: 5:20 pm – 6:30 pm)
Location:	Golden Gate Club (135 Fisher Loop, San Francisco, CA 94129, USA)
Organizers:	Alliance Forum Foundation (Organization in Special Consultative Status with the UN ECOSOC) Government of Japan
Diamond Sponsors:	DEFTA Partners Mitsui Fudosan Co., Ltd. ROHTO Pharmaceutical Co., Ltd. Shonan Health Innovation Park
Platinum Sponsors:	MUFG Union Bank, N.A. Sumitomo Dainippon Pharma Co., Ltd.
Gold Sponsors:	Chugai Pharmaceutical Co., Ltd. DeNA Healthcare
Silver Sponsors:	MS&AD Insurance Group Holdings, Inc. SanBio, Inc.
Presenter Sponsors:	Capricor Therapeutics, Inc. Fundamental Solutions Corporation Lonza Pharma & Biotech Pneuma Respiratory, Inc.
Exhibitor:	Wilson Sonsini Goodrich & Rosati
In-Kind Sponsors:	AlphaGraphics Ms. Tomoko Tsuji (IKENOBO Flower Arrangement)
Major Supporting Organizations:	Alliance for Regenerative Medicine (ARM) Forum for Innovative Regenerative Medicine (FIRM) Hara Research Foundation (HRF) Japan Bioindustry Association (JBA) Japan Pharmaceutical Manufacturers Association (JPMA)
Supporting Organizations:	Alliance Forum Foundation Executive Club BIO California BIOCOM Japanese Chamber of Commerce of Northern California (JCCNC) Japanese University Network of the Bay Area (JUNBA) Japan Society of Northern California JETRO (Japan External Trade Organization) New Energy and Industrial Technology Development Organization (NEDO) US-Asia Technology Management Center at Stanford University (US-ATMC) US-Japan MedTech Frontiers (USJMF)

Program: Thursday, November 15, 2018 (AM Session)

<Day 1> Thursday, November 15, 2018	
9:00 - 9:05	MC: Mr. Matt Gardner, Chief Executive, California Technology Council; Founding Director, The Center for Science, Technology, and Society, William Jessup University
9:05 - 9:10	Welcome Remarks The Honorable Tomochika Uyama, Consul General, Consulate General of Japan in San Francisco
9:10 - 9:15	Guest Remarks Dr. Satoshi Imamura, Vice President, Japan Medical Association
9:15 - 9:35	Opening Keynote Remarks Dr. Regis Kelly, Director, California Institute for Quantitative Biosciences (QB3)
9:35 - 10:35	Keynote Session: The Four Scientific Pillars of Aging Moderator: Dr. Regis Kelly, Director, California Institute for Quantitative Biosciences (QB3) Dr. Miyoung Chun, Co- Founder, World Without Alzheimer's Dr. Frank M. Longo, Professor & Chairman, Department of Neurology and Neurological Sciences, Stanford University Dr. Eric Verdin, CEO & President, Buck Institute for Research on Aging
10:35 - 10:55	Coffee Break /Networking
10:55 - 11:50	Panel Discussion: The Rise of Patient/Aging Activists & Their Contribution to Science Moderator: Ms. Keely Stevenson, Founder & CEO, Weal Life, PBC Ms. Julie Gregory, Co-founder & President, ApoE4.Info Ms. Ping Hao, Founder, Brand3P Dr. Michael Weiner, Professor, Department of Radiology, UCSF
11:50 - 1:00	Lunch Break (Hawthorne & Cypress Room)

Program: Thursday, November 15, 2018 (PM Session)

1:00 - 1:20	<p>Pioneering the Future with Cybernetics for the Aging Era – Fusion of Humans, Robots & Information Systems</p> <p>Dr. Yoshiyuki Sankai, Professor, University of Tsukuba; Program Manager, the ImPACT Program hosted by the Cabinet Office of Japan; President & CEO, CYBERDYNE, INC.</p>
1:20 - 2:15	<p>Panel Discussion: The Rise of The Digital Health Age</p> <p>Moderator: Ms. Maya Skubatch, Member, Wilson Sonsini Goodrich and Rosati</p> <p>Dr. Cory Kidd, Founder & CEO, Catalia Health</p> <p>Dr. James McCollum, Director of Product, Savonix</p> <p>Ms. Beth Rogozinski, CEO, Signal 2 Health</p> <p>Mr. Yoshiaki Tojo, Founder & CEO, Senesens</p>
2:15 - 2:25	<p>Company Presentation: Pneuma Respiratory, Inc.</p> <p>Mr. Rich Gimigliano, Chief Financial Officer, Pneuma Respiratory, Inc.</p>
2:25 - 2:45	<p>iPSCs-based Regenerative Medicine & Drug Development for CNS diseases</p> <p>Dr. Hideyuki Okano, Dean, Keio University Graduate School of Medicine</p>
2:45 - 3:50	<p>Panel Discussion: New Technologies: Regenerative Medicine & Advanced Therapeutics</p> <p>Moderator: Dr. Ellen G. Feigal, Partner, NDA Partners LLC</p> <p>Dr. Chihiro Akazawa, Vice Dean & Professor, Department of Biophysics, Tokyo Medical and Dental University</p> <p>Dr. Minh Hong, Associate Director of Commercial Development for Allogeneic Cell Therapy, Lonza Pharma & Biotech</p> <p>Dr. Judith Kelleher-Andersson, President & CEO, Neuronascent</p> <p>Dr. Matthias Steger, CEO, Endogena Therapeutics Inc.</p> <p>Dr. Michael West, CEO, AgeX Therapeutics, Inc.</p>
3:50 - 4:10	Coffee Break/Networking
4:10 - 4:30	<p>Contribution by Regenerative Medicine to Unmet Medical Needs in Super Aging Society</p> <p>Dr. Toru Kimura, Board Director, Drug Research Division, Regenerative & Cellular Medicine, Sumitomo Dainippon Pharma Co., Ltd.</p>
4:30 - 4:40	<p>Company Presentation: Capricor Therapeutics, Inc.</p> <p>Dr. Linda Marbán, CEO, Capricor Therapeutics, Inc.</p>
4:40 - 4:55	<p>How Changing Demands are Changing Paradigms of Care and Treatment</p> <p>Dr. Warren Browner, MD, MPH; CEO, California Pacific Medical Center (CPMC)</p>
4:55 - 5:15	<p>Case studies: Philips Healthcare and Spencer Inc.</p> <p>Mr. Steven Martin, Head of Medication Management, Philips Healthcare</p> <p>Mr. Tom Rhoads, Founder & CEO, Spencer Health Solutions</p>
5:15 - 5:35	<p>Closing Keynote Remarks: The Nobel Campaign Supporting GMOs – Food for Healthy Aging</p> <p>Dr. Richard Roberts, Nobel Laureate; CSO, New England BioLabs</p>
5:35 - 6:30	Networking & Cocktail Reception (Hawthorne Room)

Program: Friday, November 16, 2018 (AM Session)

<Day 2> Friday, November 16, 2018	
9:00 - 9:10	<p>Welcome Remarks MC: Ms. Kyoko Watanabe, Director, Alliance Forum Foundation; Managing Director, DEFTA Partners</p>
9:10 - 10:00	<p>Panel Discussion: Global Perspectives on Aging & Health Moderator: Ms. Marissa K. Fayer, CEO, HERHealthEQ Dr. Arif Dowla, CEO & Group Managing Director, ACI Group of Companies Dr. Magda Rosenmoller, Prof. IESE Business School; Academic Director, IESE Center for Research in Health Innovation Management (Barcelona, Spain) Dr. Naureen Shaikh, MD, swMBA, FAAFP, NAPCRGF; CEO, MyType</p>
10:00 - 10:10	<p>Company Presentation: Fundamental Solutions Corporation Mr. M. Russell Williams, CEO, Fundamental Solutions Corporation</p>
10:10 - 10:30	Coffee Break/Networking
10:30 - 10:50	<p>Japan's Regulations & Policies in an Aging Society Dr. Tatsuya Kondo, Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA)</p>
10:50 - 11:40	<p>Panel Discussion: Examination of Aging Trends, Policies & Regulations Moderator: Mr. Jim Sergi, President, CSSi LifeSciences Dr. William Dow, Interim Dean, School of Public Health, University of California, Berkeley Dr. John G. Haaga, Director, Division of Behavioral and Social Research, National Institute on Aging Dr. Larissa Lapteva, Associate Director, DCEPT/OTAT Center for Biologics Evaluation and Research, FDA Dr. Yasuyuki Sahara, Councilor, Minister's secretariat, Ministry of Health, Labour and Welfare, Japan</p>
11:40 - 12:50	Lunch Break (Hawthorne & Cypress Room)

Program: Friday, November 16, 2018 (PM Session)

12:50 - 1:40	<p>Panel Discussion: Market Opportunity, Reimbursement Landscape & the Rise of Preventative & Value-based Care</p> <p>Moderator: Mr. John Selig, Co-Founder & Managing Partner, WaveEdge Capital; President, WaveEdge Health</p> <p>Ms. Tina Ivovic, Senior Director of Global Reimbursement & Health Care Economics, Abbott</p> <p>Dr. Adrian McKemey, Senior Vice President & Managing Director, IQVIA</p> <p>Mr. Kazumi Nishikawa, Director, Healthcare Industries Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry, Japan</p>
1:40 - 1:50	<p>Company Presentation: Shonan Health Innovation Park</p> <p>Dr. Toshio Fujimoto, General Manager, Shonan Health Innovation Park</p>
1:50 - 2:35	<p>New Treatment Approaches</p> <p>Moderator: Dr. Rajesh Grover, Adjunct Professor, J. Craig Venter Institute</p> <p>Dr. Dale Bredesen, Professor, UCLA; Founding President, Buck Institute</p> <p>Dr. Karoly Nikolich, CEO & Chairman of the Board of Directors, Alkahest Inc.</p>
2:35 - 2:45	<p>Funding Trends</p> <p>Mr. Jonathan Norris, Managing Director, Life Science & Healthcare Practice, Silicon Valley Bank</p>
2:45 - 3:05	Coffee Break/Networking
3:05 - 3:55	<p>Panel Discussion: Funding Start-ups Focused on Longevity</p> <p>Moderator: Ms. Elona Baum, Managing Director, DEFTA Partners</p> <p>Ms. Laura Deming, Founder, Longevity Fund</p> <p>Mr. Karl Handelsman, Director, Investments, Roche Venture Fund</p> <p>Dr. Chris Haskell, Vice President & Head of the West Coast Innovation Center, Bayer</p> <p>Mr. Mike Suiters, Vice President, Sandbox Industries</p>
3:55 - 4:05	<p>The Future of Human Purpose</p> <p>Ms. Julie Friedman Steele, CEO, World Future Society</p>
4:05 - 5:00	<p>Keynote Panel: Action Challenge</p> <p>Moderator: Dr. Regis Kelly, Director, California Institute for Quantitative Biosciences (QB3)</p> <p>Dr. Warren Browner, MD, MPH; CEO, California Pacific Medical Center (CPMC)</p> <p>Ambassador George Hara, Chairman of the Board, Alliance Forum Foundation; Group Chairman & CEO, DEFTA Partners; Special Advisor to the Cabinet Office of the Prime Minister of Japan</p> <p>Dr. Karoly Nikolich, CEO & Chairman of the Board of Directors, Alkahest Inc.</p> <p>Dr. Richard Roberts, Nobel Laureate; CSO, New England BioLabs</p>
5:00 - 5:20	<p>Concluding Remarks</p> <p>Ambassador George Hara, Chairman of the Board, Alliance Forum Foundation; Group Chairman & CEO, DEFTA Partners; Special Advisor to the Cabinet Office of the Prime Minister of Japan</p>
5:20 - 6:30	Networking & Cocktail Reception (Hawthorne Room)

Speakers: Thursday, November 15, 2018 (AM Session)



Tomochika Uyama
Consul General of Japan
in San Francisco

Consul General Tomochika Uyama began his career with the Ministry of Foreign Affairs of Japan in 1986 and has been involved in the diplomatic service for over 30 years. His assignments overseas have included postings in Egypt, the Philippines, the Republic of Korea, and the Permanent Mission of Japan to the International Organizations in Geneva. His domestic assignments in Tokyo have included positions at the Economic Affairs Bureau, Latin American and Caribbean Affairs Bureau, and in the Ministry of International Trade and Industry.



Satoshi Imamura
Vice President,
Japan Medical Association

Dr. Satoshi Imamura graduated the Akita University Faculty of Medicine in 1977. His specialty is anesthesiology. He firstly worked as resident in the Mitsui Memorial Hospital in 1977 to 79. He worked for the Hamamatsu University School of Medicine from 1983 to 1987. After that he served as department chief of the Shizuoka General Hospital. He has been working as Director of Imamura Clinic since 1991. He was serving as a Board Member of the Tokyo Medical Association in 2004 to 2006. He was also serving as an Executive Board Member of the Japan Medical Association (JMA) in 2006 to 2012. He has been working as Vice-President of the JMA since 2012. At the JMA, he is mainly in charge of general affairs, **health policy, financial affairs, member's welfare, pension, taxation policy and public health. He is a core member of many important committees of the Ministry of Health, Labor and Welfare related to the restructuring of the social security system, cancer screening system, advanced clinical training program and others. He is also involved in the areas as a committee member of the public organizations for health protection of the workers such as the industrial health program, life-style related diseases control, safety in the work place, and many others.**



Regis B. Kelly
Director, QB3

Dr. Regis B. Kelly is the Director of QB3, one of the four California Institutes for Science and Innovation. The QB3 innovation team converts discoveries into practical benefits for society. As Director, Dr. Kelly helped launch two QB3-associated companies, QB3@953, a Life Sciences Startup incubator and Mission Bay Capital, a venture fund. As a result of his experiences, Dr. Kelly was seconded as Senior Advisor on Innovation and Entrepreneurship to the President of the University, Janet Napolitano in 2014 and 2015.

Prior to joining QB3 in 2004, Regis Kelly served as executive vice-chancellor at UCSF and Chairman of the Department of Biochemistry and Biophysics. He holds the inaugural Byers Family Distinguished Professorship. His academic research was in the field of molecular and cellular neurobiology. His training was at Harvard, Stanford, Caltech and the University of Edinburgh. He has served on many national and international boards. In 2014 he was appointed an officer of the Order of the British Empire (OBE) for services to science, innovation, and global health.



Miyoung Chun
Co-Founder,
World Without Alzheimer's

Dr. Miyoung Chun is **Co-Founder of the World Without Alzheimer's (WWA). The WWA aims to reconfigure the landscape for the Alzheimer's crisis through expanding the Alzheimer's scientific research with strong funding mechanisms and building new financial structures with innovative business models to accelerate prevention, treatment, and cure for the Alzheimer's dementia.**

Dr. Chun leverages 30 years of experience in academia, industry, and philanthropy to transform ideas into reality and orchestrate strategic multi stakeholder initiatives. She has been a professor at Boston University School of Medicine, an assistant dean at UC Santa Barbara, and a project leader at Millennium Pharmaceuticals. As Executive Vice President of Science Programs at The Kavli Foundation, she managed 20 research institutes around the world and launched, catalyzed, and shepherd national and global scientific projects, including the U.S. BRAIN Initiative, the Unified Microbiome Initiative, and the HUMAN Project.

Where ever she goes, Miyoung brings her signature energetic passion for imagining blue-sky ideas and delivering big, game-changing results. She obtained her Ph.D. in molecular genetics at the Ohio State University and performed her post-doctoral research in cell biology and biochemistry at MIT, Whitehead Institute.



Frank M. Longo
 Professor & Chairman,
 Department of Neurology
 and Neurological Sciences,
 Stanford University

Dr. Frank M. Longo is Professor and Chairman, Department of Neurology and Neurological Sciences at Stanford University, and serves on the Advisory Committee for the Stanford Neurosciences Institute. He completed his neurology training in the Department of Neurology at UCSF where he also served as professor and vice chair. Since 2006, he has been chair of the Department of Neurology and Neurological Sciences at Stanford. While at Stanford, Dr. Longo has led the recruitment of close to 100 faculties and has **overseen the development of major clinical programs in stroke, epilepsy, Alzheimer’s, Parkinson’s, autonomic disorders, headache, and other neurological areas.** He has also prioritized excellence in education with Stanford School of Medicine students rating neurology as their top clinical core rotation for 8 out of the past 9 years. In the area of research, Dr. Longo has led a major research expansion in Stanford neurology with the department recently ranked among the top 5 in the US in NIH funding. Within his own research efforts, Dr Longo is one of the rare physician-scientists who has advanced an approach starting at basic mechanism elucidation through preclinical trials and into human trials. With support from the NIH and generous donations, he and his team have pioneered an entirely new pharmaceutical approach for the **treatment of Alzheimer’s disease and other neurodegenerative disorders. He founded Pharmatrophix,** with his wife Anne Longo as CEO, a company focused on the commercial development of treatments for **Alzheimer’s and other diseases. In 2015, Dr. Longo was the recipient of the inaugural Goodes Prize for Excellence in Alzheimer’s Drug Discovery from the Alzheimer’s Drug Discovery Foundation. In February 2016, his lead drug was featured on the cover of TIME Magazine.**



Eric Verdin
 CEO & President,
 Buck Institute for Research
 on Aging

Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a professor of medicine at University of California, San Francisco.

Dr. Verdin studies how metabolism, diet, and small molecules regulate the activity of HDACs and sirtuins, **and thereby the aging process and its associated diseases, including Alzheimer’s. He has published more than 210 scientific papers and holds more than 15 patents.** He is a highly cited scientist (top 1 percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of National Institute on Drug Abuse at the National Institutes of Health.



Keely Stevenson
 Founder & CEO,
 Weal Life, PBC

Keely Stevenson is an entrepreneur and an investor. She is CEO and Co-founder of Weal Life, a digital health company focused on leveraging mobile technology to make it easier for people to care for each other during times of health crisis, aging or chronic illness. She recently joined the board of the Family Caregiver Alliance and has served as a board member, mentor and advisor to start-ups and established **companies in healthcare, biotech, energy, education and finance around the globe. Previously, she’s built global initiatives, including in her role as CEO of Bamboo Finance USA. Bamboo is one of the world’s first and largest private equity firms focused on balancing social impact and commercial returns (\$300M AUM). She’s also built the world’s first online community for social entrepreneurs (Social Edge) as she was the first employee hired by the CEO of Skoll Foundation.** She has worked on five continents building the field of social entrepreneurship with the United Nations, Acumen Fund, Triodos Bank, Royal Bafokeng Nation and the California Legislature. Keely has lectured around the world on topics such as impact investing, women’s leadership, aging, caregiving and healthcare. She studied politics at UC Berkeley and received an MBA from Oxford University where she was a Skoll Scholar. Keely was awarded the honor of being a Young Global Leader at the World Economic Forum. She is passionate about highlighting diversity of all sorts contributing to tech and human development globally.



Julie Gregory
Co-founder & President,
ApoE4.Info

Julie is a founder and president of ApoE4.Info, a non-profit focused on learning about the ApoE4 gene. This vibrant online community is disrupting mainstream medicine by connecting carriers of the gene **with Alzheimer's researchers from all over the world to identify strategies to prevent, and even mitigate**, symptoms of cognitive decline. ApoE4.Info works to translate emerging science into clinical practice often cultivating N=1 experimentation amongst its members. Julie is trained as a marriage and family therapist and has focused much of her career on helping families as an advocate for children. When her own son became critically ill at age 12 with multiple, supposedly unrelated medical conditions, she found herself becoming his advocate within a medical community that offered no hope. She made novel connections from published medical literature that ultimately lead to his recovery. When she learned of **her high genetic risk for Alzheimer's disease, she transferred these skills to help her navigate a very similar landscape**. Julie also runs a consulting business focused on the ApoE4 gene and has partnered with Dr. Dale Bredesen to help write the sequel to *The End of Alzheimer's* which will feature a step-by-step handbook, available in the spring of 2019.



Ping Hao
Founder, Brand3P

Ping most recently led the growth of Walmart.com's global e-commerce Marketplace as Associate Director, managing partner acquisition, onboarding, and engagement teams. She was part of the founding team since 2015 that built and grew Marketplace into representing over 90% of the assortment on Walmart.com today, with over 20,000 professional, vetted sellers. Her proudest contributions have been to initiate the vision and launch of the family caregiving experience, and the officially licensed U.S. Military and the supplier diversity/inclusion eCommerce showcases on Walmart.com which garnered broad industry and press recognition. Ping just started her own company, Brand3P, where she will be working closely with brands and retailers to scale at the speed of eCommerce with a marketplace data services platform. Ping has been an executive at the largest corporations as well as multiple startups, enjoying the building of new product innovation, market acceleration, and consumer adoption. Her career began as a design engineer for Hewlett-Packard's **first family of RISC workstations which she followed to market and sold world-wide to build the world's next generation computing technologies**. She is widely recognized for her passion for building affinity networks, including her leadership with the Family Caregiver Alliance (Board President and Board member/advisor (2007- present)) and the Harvard Business School (HBS) Association of Northern California (President (2007-2012, 2013-2015) and currently Advisory Council (2015-present)). From 2014-2017, she served on the global HBS alumni Board of Directors nominated by Dean Nitin Nohria. Ping holds an MBA from Harvard Business School and a BSEE from Cornell University.



Michael Weiner
Professor, Department of
Radiology, UCSF

Michael Weiner, MD, is a Professor in Residence in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principle Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. After graduating from the Johns Hopkins University in 1961, He obtained his M.D. from SUNY Upstate Medical Center in Syracuse, New York in 1965, and he completed his internship and residency in Medicine from Mt. Sinai Hospital in 1967. From 1967-1968, Dr. Weiner completed a residency and clinical fellowship in Metabolism from Yale-New Haven Medical Center. In 1970, he completed a research fellowship in Nephrology from Yale University School of Medicine and a research fellowship in Biochemistry from the University of Wisconsin Institute for Enzyme Research in 1972, followed by a joint appointment in the Department of Medicine, Renal Section from the University of Wisconsin Institute in 1972. In 1974 he became an Assistant Professor of Medicine (Nephrology) at Stanford University, and in 1980 he became an Associate Professor of Medicine (Nephrology) at UCSF. In 1983, he established the Magnetic Resonance Unit at the San Francisco VA Medical Center, which became the Center for Imaging of Neurodegenerative Diseases in 2000. In 1990, he became a Professor of Radiology, Medicine, Psychiatry and Neurology at UCSF.

Dr. Weiner's research activities involve the development and utilization of MRI and PET for investigating and diagnosing neurodegenerative diseases. In 1980, Dr. Weiner was one of the first to perform MRS on an intact animal, and subsequently pursued his goal to develop MRI/S as a clinical tool. During the past 25 years he has worked to develop and optimized the use of MRI, PET, and blood based biomarker **methods to diagnose Alzheimer's disease and other neurodegenerative disorders. Also, Dr. Weiner's research focuses on monitoring effects of treatment to slow progressions in Alzheimer's disease, and detecting Alzheimer's disease early in patients who are not demented, but risk subsequent development of dementia. He is the Principle Investigator of the Alzheimer's Disease Neuroimaging Initiative which has enrolled over 1500 subjects (including controls, MCI, and AD) at 68 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture.** He has also launched The Brain Initiative, which is a web-based registry for recruiting, screening, and longitudinally monitoring subjects for neuroscience studies of all types. Dr. Weiner has 649 published articles and he has written 70 book chapters.

Speakers: Thursday, November 15, 2018 (PM Session)



Yoshiyuki Sankai
Professor, University of
Tsukuba; Program
Manager, ImPACT;
President & CEO,
CYBERDYNE, INC.

Yoshiyuki Sankai has progressed from being an assistant professor in University of Tsukuba and a visiting professor at Baylor College of Medicine in the United States. Currently, he is a professor and Executive Research Director at the Center for Cybernetics Research, University of Tsukuba; the President and CEO of CYBERDYNE, INC. (established as a university venture in 2004, and is listed with the Mothers section of the Tokyo Stock Exchange from 2014); and a Program Manager of the Impulsing Paradigm Change through Disruptive Technologies (ImPACT) program initiated by the Cabinet Office in Japan. He is a fellow of the RSJ and SICE. He is also a member of Global Future Council of the World Economic Forum and a Center Partner of the Center for the Fourth Industrial Revolution of World Economic Forum.



Maya Skubatch
Member,
Wilson Sonsini Goodrich and
Rosati

Maya Skubatch is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she focuses on strategic patent counseling for healthcare companies. She represents both private and public companies and works closely with licensing, litigation, corporate, and regulatory counsel to provide her clients with a holistic IP strategy. Maya is personally passionate about the regenerative medicine space and works with numerous companies developing both drugs and food supplements to enhance health. She also helps companies in the healthcare IT space to monitor healthy living.



Cory Kidd
Founder & CEO,
Catalia Health

Dr. Cory Kidd is the founder and CEO of Catalia Health. Dr. Kidd has been working in healthcare technology for nearly two decades. The focus of his work has been applying innovative technologies towards solving large-scale healthcare challenges. His previous company, Intuitive Automata, created interactive coaches for weight loss. Prior to this, Dr. Kidd received his M.S. and Ph.D. at the MIT Media Lab in human-robot interaction. While there, he conducted studies that showed the psychological and clinical advantages of using a physical robot over screen-based interactions.



James McCollum
Director of Product,
Savonix

Dr. McCollum is a clinical psychologist and Director of Product at Savonix. Savonix delivers a set of cognitive assessments on iOS and Android-based smartphones and tablets. Dr. McCollum's work focuses on providing evidence-based cognitive testing to populations around the world, many of whom have not historically had access to professional cognitive testing. Previously, he has been a visiting professor at California School of Professional Psychology, an independent research consultant, and a practicing clinician.



Beth Rogozinski
CEO,
Signal 2 Health

Beth Rogozinski is a serial entrepreneur, technology professional, and business strategist who has spent the last several years focused on digital medicine. Beth has worked in hardware, software and services at such top firms as Silicon Graphics, Macromedia, and the digital agency Circle and has also founded games and apps companies including Signal 2 Productions, Match Factor and D2S Games. She has produced and published more than 30 games and apps, including over a dozen apps for health and wellness. **At Pear Therapeutics, Beth served as Chief Product Officer and led the development of Pear's first clinical product, reSET, and the product team submission of the De Novo 510k to the FDA which was cleared by the FDA in 2017 as the first ever prescription digital therapeutic.** Beth is an advisor to many start-ups and accelerators and has consulted with local and international venture groups around digital health investments. **Beth serves on the Biotechnology Innovation Organization's educational programs committees for Digital Health and chairs the program for Brain Health.** She has written and published on digital therapeutics and tech innovations and is a frequent speaker at technology and healthcare events.



Yoshiaki Tojo
Founder & CEO,
Senesens

After serving as Head of JETRO San Francisco, Yoshi TOJO launched his entrepreneurial project Senesens last year, developing voice-based relational agent for successful aging. It aims to encourage people to attend to the factors under their control, such as diet, sleep, exercise, and emotional wellness, in order to reduce the risk and delay the onset of age-related diseases.

Yoshi TOJO has long been engaged in R&D management and technology commercialization, and contributed to various translational research projects in IT and healthcare at Japanese government agencies, OECD, and Kyoto University. Along with his own startup endeavor, Yoshi currently provides consultation services and seed-stage investments for technology startups.



Rich Gimigliano
Chief Financial Officer,
Pneuma Respiratory, Inc.

Rich Gimigliano brings over thirty years of Wall Street experience across a wide variety of investment banking and capital markets roles to the Chief Financial Officer position at Pneuma Respiratory, Inc. Rich started his financial career at Credit Suisse First Boston (CSFB) as a member of the New York institutional equity sales and trading desk. He quickly rose to a senior production position covering **institutional investors and was subsequently asked to join CSFB's West Coast effort. After helping grow that team, he was recruited by Lehman Brothers where he ultimately managed the firm's US equity sales trading business.** Senior positions at Montgomery Securities and Thomas Weisel Partners led to increasing involvement in investment banking and transaction origination and execution. Over the last decade he has continued to focus on helping fast-growing companies access the capital markets.

Rich has a BSEE with honors from Lehigh University and an MBA from the University of North Carolina at Chapel Hill.



Hideyuki Okano
Dean,
Keio University Graduate
School of Medicine

Hideyuki Okano received M.D. in Physiology from Keio University in 1983. After he obtained Ph.D. degree from Keio University in 1988, he held post-doctoral position at Johns Hopkins University Medical School. He has appointed full professors at Tsukuba University School of Medicine in 1994, Osaka University School of Medicine in 1997, and returned to Keio University Medical School in 2001 as a full professor of Physiology. Since 2007, he has been a Dean of Keio University Graduate School of Medicine or a Dean of Keio University School of Medicine. He has been conducting basic research in the field of regenerative medicine including, neural stem cells and iPS cells, spinal cord injury, developmental genetics and RNA binding proteins. He has awarded numbers of awards and honors including the Medal with Purple Ribbon in 2009 and the first prize of the 51st Erwin von Bälz Prize in 2014. He aims to establish and provide patients-specific iPS cells and genetically modified non-human primate models for neuroscience research and to explore the pathogenic mechanisms of neurological/psychiatric disorders. Currently, he is the leader of Brain Mapping Project in Japan (Brain/MINDS).



Ellen G. Feigal
Partner,
NDA Partners LLC

Dr. Feigal is a Partner in NDA Partners, a global strategy consulting firm specializing in expert product development and regulatory development and regulatory advice to medical product developers. She was formerly Senior Vice President of Research and Development at the California Institute for Regenerative Medicine; Executive Medical Director, Global Development, at Amgen; and Chief Medical Officer at Insys Therapeutics. Dr. Feigal was a founding Director of the American Course on Drug Development and Regulatory Sciences. The course was developed under her leadership as a collaborative effort with **the FDA, UC San Francisco's Department of Bioengineering and Therapeutic Sciences, its Center for Drug Development Sciences, and the European Center of Pharmaceutical Medicine at the University of Basel.** She has worked in clinical research and product development in positions at the Federal Government and non-profit institutes including Director of Medical Devices and Imaging at the Critical Path Institute, and Vice President of Clinical Sciences and Deputy Scientific Director at the Translational Genomics Research Institute. She directed the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis after serving as Deputy Director, and was a senior investigator in the Cancer Therapy Evaluation Program. Dr. Feigal earned an MD at UC Davis, completed an internal medicine residency at Stanford, and a hematology/oncology fellowship at UC San Francisco. She was on the faculty at UC San Francisco, and UC San Diego, before joining the NCI, and is an Adjunct Professor **in the Sandra Day O'Connor College of Law, where she teaches classes on medical research ethics, and on FDA drug law.**



Chihiro Akazawa
Vice Dean & Professor,
Department of Biophysics,
Tokyo Medical and Dental
University

Chihiro Akazawa, MD, PhD, is the Vice Dean and the professor of Department of Biochemistry and Biophysics, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. He received PhD from TMDU after the clinical training at the Department of Internal Medicine, University Hospital of TMDU, followed by post-doctoral training with Dr. Stefan F. Heinemann at the Salk Institute for Biological Studies. His research field is the somatic stem cell research such as skeletal satellite cells. He is also serving as a Program Supervisor of the Research Center Network of Regenerative Medicine, AMED, Japan.



Minh Hong
Associate Director of
Commercial Development for
Allogeneic Cell Therapy,
Lonza Pharma & Biotech

Dr. Minh Hong is the Head of Allogeneic Cell Therapy at Lonza. Lonza is a Swiss company with a strong focus on process development and contract manufacturing of therapeutic materials including small molecules, biologics, viruses and cells. Currently, Dr. Hong is the global commercial development **director for Lonza's allogeneic business, which includes manufacturing sites in the US, Europe, and Asia.** Prior to this, he functioned as a strategic account and business development manager for some of **Lonza's top Cell and Gene Therapy clients. Dr. Hong holds a Ph.D. degree from the University of Minnesota, and completed postdoctoral studies at the University of Minnesota and Harvard University.**



**Judith Kelleher-
Andersson**
President & CEO,
Neuronascent

Dr. Kelleher-Andersson has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. She founded Neuronascent, raised equity, obtained State and Federal funding aimed at discovering novel neuron regenerative therapies that address chronic neurodegenerative disorders. One of these therapies is now an IND-enabled, patented, first-in-category therapy to reverse age-related disorders. Prior to founding Neuronascent, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Scientist at Cortex **Pharmaceuticals, Inc. She headed the Alzheimer's disease program in collaboration with Astra (later AstraZeneca) while at Centaur, and successfully brought a small-molecule agent she invented (primary inventor) to pre-nomination status.** She invented a neurogenic antidepressive therapeutic, that has now completed Phase IIb, while at Neuralstem. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received a B.A. in chemistry from St. Anselms College, her Ph.D. in biochemistry from University of Missouri-Columbia and completed post-graduate work at UCLA under a NIH-Mental Retardation Fellowship and at University of California, San Francisco in the Neurology Dept.



Matthias Steger
CEO,
Endogena Therapeutics Inc.

Matthias Steger is CEO of Endogena Therapeutics Inc., a new biotech company focusing on the discovery and development of endogenous regenerative medicines. Prior to Endogena, he worked 18 years in the field of drug discovery, most recently as Global Head of Research & Technology Partnering, at Roche, setting up and managing > 50 collaborations and acquisitions for novel drug modalities, new drug discovery technologies, as well as enabling technologies, such as translational models, biomarkers, and drug delivery/formulation. Matthias has also lead and implemented various corporate strategies **exploring novel drug discovery approaches, and as such has initiated and built up Roche's stem cell research.**

In addition, Matthias worked as an independent consultant for various biotech companies, academic institutes and venture capital firms, exploring novel drug discovery – and partnering / investment strategies. He also has prior entrepreneurial experience by building up a pioneering orphan GPCR drug discovery company, which lead to a successful acquisition. Matthias started his career in research, as a medicinal chemist at Roche, exploring novel platforms and drug design approaches, as well as traditional drug discovery programs. He also gained a financial perspective of the industry as an investment banking analyst at Kepler Equities.

He served as an executive board member of the Alliance for Regenerative Medicine (ARM), as well as the chair of the industry committee of the International Society of Stem Cell Research (ISSCR). Matthias has a Diploma in Organic Chemistry (University of Zürich, Switzerland), and a PhD in Medicinal Chemistry from the University of Sussex, UK, as well as an MBA from HSG (St. Gallen, Switzerland).



Michael West
CEO,
AgeX Therapeutics, Inc.

Michael D. West, Ph.D. is the founding CEO of AgeX Therapeutics, a biotechnology company focused on interventional gerontology, and a subsidiary of BioTime, Inc. where he also serves as Co-CEO, having joined as CEO in 2007. Prior to BioTime he served in a variety of roles including Chairman, CEO and CSO at Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in 2016 for \$379 Million.

In 1990 Dr. West founded what was likely the first regenerative medicine company, Geron (Geronology) Corp. with backing from Kleiner, Perkins, Venrock and others. For its scientific team he recruited Drs. Elizabeth Blackburn, Carol Greider and Jack Szostak, who collectively went on to win the Nobel Prize in Medicine and he created the research consortium with Prof. James Thomson that led to the first isolation of human embryonic stem cells.

Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. in Biology from Andrews University in 1982, and a Ph.D. with a concentration on the biology of cellular aging from Baylor College of Medicine in 1989. The author of numerous articles in peer-reviewed scientific journals, he wrote *The Immortal Cell: One Scientist's Quest to Solve the Mystery of Human Aging* (DoubleDay, 2003), and has testified before the U.S. Congress about the potential lifesaving benefits of regenerative medicine.



Toru Kimura
Board Director,
Drug Research Division,
Regenerative &
Cellular Medicine,
Sumitomo Dainippon
Pharma Co., Ltd.

Dr. Toru Kimura has been working for Sumitomo Dainippon Pharma as a Member of the Board of Directors since 2016. On his strong basis of science, he has been leading Drug Research Division and Regenerative & Cellular Medicine business

Toru joined Sumitomo Chemical Co., Ltd. in 1989 and the former Sumitomo Pharmaceuticals in 1992 as a scientist. He led Genomic Science Laboratories in 2009, and Research Planning and Management Group in 2010. After a Director of Global Strategy Group, he has been an Executive Officer of the Company since 2015. Also, with a long-term effort in stem cell research, he established Regenerative & Cellular Medicine Office in 2013 where there are a lot of collaborative research and development with academia and industries. He and his team recently completed a cell manufacturing plant SMaRT (Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine and Cell Therapy).

He has a Ph.D. from Kyoto university, and studied at Massachusetts General Hospital and Harvard Medical school as a visiting scientist.



Linda Marbán
CEO,
Capricor Therapeutics, Inc.

Linda Marbán, Ph.D. Dr. Marbán is currently serving as our Chief Executive Officer, and has served in that capacity and on the Board since November 2013. As co-founder of Capricor, Inc., our wholly-owned subsidiary, Dr. Marbán has been with Capricor, Inc. since 2005 and became its Chief Executive Officer in 2010. She combines her background in research with her business experience to lead the Company and create a path to commercialization for its novel therapies. Dr. Marbán was the lead **negotiator in procuring the license agreements that are the foundation of the Company’s intellectual property portfolio.** Under her direction as Chief Executive Officer, the Company has secured over \$30.0 million in non-dilutive grant awards which have funded our research and development programs and a **loan award which funded Capricor, Inc.’s ALLSTAR clinical trial.** **Dr. Marbán’s deep knowledge of the cardiac space, in particular, allows her to provide unique direction for the Company’s development and growth.** From 2003 to 2009, Dr. Marbán was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. **utilizing Excigen’s technology and supervised the building of a lab in which the work was to be performed.** Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a **postdoctoral fellowship at Johns Hopkins University (“JHU”).** **While at JHU, she advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure.** Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology.



Warren Browner
MD, MPH;
CEO, California Pacific
Medical Center (CPMC)

Warren Browner has been with Sutter Health CPMC since 2000. He joined the affiliate as the Vice-President, Academic Affairs and Scientific Director, CPMC Research Institute. In 2009 he assumed the position of CEO of California Pacific Medical Center (CPMC). He is also a board-certified internist; Clinical Professor of Medicine, Geisel School of Medicine at Dartmouth College; and, Professor (adjunct) of Epidemiology & Biostatistics at the University of California, San Francisco (UCSF).

Prior to joining CPMC, Dr Browner was a full-time faculty member at UCSF for 15 years, serving as Chief of General Internal Medicine and Acting Chief of the Medical Service at the San Francisco VA Medical Center.

He has served as Executive Editor of the American Journal of Medicine for seven years. He has been a member of Federal panels for the National Institutes of Health, the Department of Veterans Affairs, and the Food and Drug Administration. He teaches courses in clinical research design and on publishing clinical research at CPMC and at UCSF; in addition, he continues to teach seminars on both topics at various national meetings.

He also currently volunteers to serve as Immediate Past Chair, Board of Directors of the Jewish Community Center of San Francisco; Board member of the Hospital Quality Institute, California Hospital Association (CHA); and Chair, Quality Committee of the CHA.

Dr Browner earned an A.B. from Harvard College; an M.D. from UCSF; a Master’s degree in Public Health (M.P.H.) in Epidemiology from UC Berkeley; and he completed a residency in internal medicine and a fellowship in clinical epidemiology at UCSF.



Steven Martin
Head of Medication
Management,
Philips Healthcare

As Head of Medication Management for Philips Connected Insights and Care, Steven Martin focuses on how to integrate technology seamlessly into solutions to improve medication adherence and engagement of chronically-ill patients. As care moves from the hospital to lower cost settings, including the home, medication management is integral to develop aggregated patient data and understand the health needs within patient populations. During his tenure at Philips, Steven has led product and marketing efforts to increase the scope and awareness around medication management and integration within multiple Philips business ventures. Steven developed the Philips Medication Adherence Solution platform which won the 2018 Frost and Sullivan award for Enabling Technology Leadership in Medication adherence. Steven joined Philips in 2015 after working globally in the medical device industry for many years.



Tom Rhoads
Founder & CEO,
Spencer Health Solutions

Tom Rhoads has been leading the development and launch of healthcare technology for 25 years. He is a widely-published thought leader and was invited to introduce spencer® to an international health innovation audience during the 2017 Cannes Lions Health Festival. Tom holds four pharmacy automation patents, with two additional patents pending.

Prior to his current role as Founder and CEO of spencer Health Solutions, Rhoads was CEO of Parata Health Systems. Under his leadership, Parata launched the first and only next-generation pharmacy automation and today the company supports almost 9,000 pieces of automation in the market to fill about **10% of all prescriptions in the United States. Additionally, it was under Rhoads' leadership that Parata** successfully began deploying the multi-medication packs that pharmacists now use to pre-package refills for use in spencer technology. His previous industry experience includes Baxter Healthcare and Cardinal Health Corporation, where he held positions as director of marketing, director of information technology and project director of manufacturing. Tom is a graduate of Duke University, with an MBA from The Citadel. He is an Iron Duke Alumnus and member of the North Carolina Technology Association and the Chief Marketing Officer Council.

Tom also serves on the board of Pharmacy Times, and is a member of the Young Presidents Organization. He is a member of the Advisory Panel Member for the Centers for Medicare and Medicaid Innovation (CMMI) Services, Payment and Program Evaluation grant in North Carolina.



Richard Roberts
Nobel Laureate;
CSO, New England BioLabs

Dr. Richard J. Roberts is the Chief Scientific Officer at New England BioLabs, Beverly, Massachusetts. He received a Ph.D. in Organic Chemistry in 1968 from Sheffield University and then moved as a postdoctoral fellow to Harvard. From 1972 to 1992, he worked at Cold Spring Harbor Laboratory, eventually becoming Assistant Director for Research under Dr. J.D. Watson. He began work on the newly discovered Type II restriction enzymes in 1972 and these enzymes have been a major research theme. Studies of transcription in Adenovirus-2 led to the discovery of split genes and mRNA splicing in 1977, for which he received the Nobel Prize in Medicine in 1993. During the sequencing of the Adenovirus-2 genome computational tools became essential and his laboratory pioneered the application of computers in this area. DNA methyltransferases, as components of restriction-modification systems are also of active interest and the first crystal structures for the HhaI methyltransferase led to the discovery of base flipping. Bioinformatic studies of microbial genomes to find new restriction systems are a major research focus as is the elucidation of DNA methyltransferase recognition sequences using SMRT sequencing and a new approach to m5C containing recognition sequences.

Master of Ceremonies



Matt Gardner
Chief Executive,
California Technology
Council;
Founding Director,
The Center for
Science, Technology,
and Society, William
Jessup
University

Matt Gardner is the chief executive of the California Technology Council and the Founding Director of the Center for Science, Technology, and Society of William Jessup University.

Matt previously founded or cofounded industry organizations including the California Cybersecurity Information Sharing Organization, BioCalifornia, California Business Incubation Alliance, the California Technology Council, Bay Area Bioscience Association, and the California Biotechnology PAC. Matt has served as the chief executive of the California Technology Council, Cancer Commons, BayBio and the Maryland Bioscience Alliance. He is an active member of the board in innovation bodies including the Technology Councils of North America, California Cybersecurity Task Force, and the Information Sharing and Analysis Organizations Standards Organization. Matt is currently chair of the National Council of Registered ISAOs.

He has served as a member of the adjunct faculty at the University of San Francisco in the Department of Entrepreneurship and Innovation in the School of Management.

Matt has also had a hand as a co-founder, early board member and advisor to a number of startups including Ruly, LNG Energy, TriGuard Risk Solutions, BioXiness, Farmatic, Jujama, the Patent & License Exchange, and others.

Matt Gardner is author or co-author of publications on innovation including “California Tool Works,” a landmark study of incubators and accelerators in California, “Approaching Zero” and “A Future at Risk,” studies on the delicate ecosystem for seeding new companies, and the award-winning “Impact” annual reports on life sciences.

Matt is a contributing writer to “Medtech Insight” and several other publications. He is also executive producer of the radio program Tech Nation, heard on NPR, SiriusXM and American Forces Radio. His campaigns have won awards including the Silver Anvil Award of the Public Relations Society of America, for the BayBio’s “Impact” reports, and an Emmy Award for the “Behind the Science of Life” television campaign.

He was, until recently, chairman of the board of Seeding Labs, a non-profit based in Cambridge, Massachusetts which improves science capacity at institutions in the developing world. He has also served on the board of the Exploratorium Lab, a science museum in the San Francisco Bay Area. Matt has demonstrated leadership in the community through previous board memberships including the California Association for Local Economic Development, Team California, California Commission for Economic Development, the Alameda County Workforce Investment Board, the Maryland Technology Development Center, and Montgomery Works, the workforce board in Montgomery County, Maryland. He has served on boards at the Council of State Bioscience Associations, University of Maryland and Johns Hopkins University. Matt chaired organizations including the State Medical Technology Alliance, Maryland Venture Capital Task Force, Maryland Clinical Development Initiative, and US-Queensland Bioscience Business Council, while serving as the U.S. biotechnology leader for the state government of Queensland, Australia.

He served as a founder and chair of the life science innovation boards for two members of Congress, Rep. Barbara Lee (California, 13th) and Rep. Jackie Speier (California, 14th). He is the co-author of legislation including Maryland’s angel investment credit and California’s tax treatment of net operating losses for innovative companies, and regulations including California’s “L” occupancy code allowing life sciences research to expand vertically above the second floor.

He earned his Bachelor of Arts in Political Science and his Master of Arts in History, both from the University of San Diego. His Master’s thesis, entitled The Seeds of Innovation, explored the roots of San Diego’s biotech and telecommunications industry development.

Speakers: Friday, November 16, 2018 (AM Session)



Marissa K.
Fayer
CEO,
HealthEO

Marissa Fayer is an 18-year medtech executive, entrepreneur, and philanthropist. She is the president of consulting firm Fayer Consulting LLC, the CEO and founder of non-profit HERHealthEO, and a partner at direct investment platform LLEX Partners. Her mission is health equity for women and works to advance growth and prosperity for organizations and the communities in which they operate by increasing efficiency, raising capital, and enhancing partnerships.

Marissa has previously served as an executive at Hologic, Olympus (formerly ACMI), Maquet-Getting (formerly Atrium Medical), Providien Medical, and Accumed Innovative Technologies.

Marissa leads the #wealththroughhealth and #healthequityforwomen movements and is dedicated to health equity for women around the world.

Twitter: @mkfayer and @HERHealthEO
LinkedIn: <https://www.linkedin.com/in/marissa-fayer-mba-b788451/>
Facebook: <https://www.facebook.com/marissa.fayer>
Instagram: mfayer19



Arif Dowla
CEO & Group Managing
Director,
ACI Group of Companies

Dr. Arif Dowla has been the Group CEO for 13 years of one of the largest business conglomerates in Bangladesh, having 37 business units and 17000+ employees. Main businesses are Pharmaceuticals, Biotechnology, Agribusiness, Consumer Brands, Retail Chain, Motors and Plastics. Several of the businesses are market leaders in the country. Most of the Business are linked to the underlying development of the economy of Bangladesh in critical and enabling growth sectors. Technology adoption and digitalization are **core focus areas for driving the growth of the businesses**. **ACI Group won “Enterprise of the Year” award from DHL-Daily Star in 2011**. Dr. Arif Dowla served as Chairman of Mutual Trust Bank for two years (2012-2014) and Vice Chairman for four years (2007-2011). He appointed as Honorary Consul of Belgium in Bangladesh since 2011. He was Young Global Leader honoree of the World Economic Forum in 2009. Dr. Dowla holds a Ph.D in Mathematics from University of California, San Diego and is a member of the American Mathematical Society.



Magda
Rosenmoller
Professor, IESE
Business School;
Academic Director,
IESE Center for
Research in Health
Innovation
Management,
Barcelona, Spain

Magda Rosenmoller holds a Ph.D. in Health Policy (University of London), a Medical Doctor (University Louis Pasteur, Strasbourg, France), and an MBA from IESE. She teaches the MBA elective on health innovation management at IESE, and health executive education in European, Asian, African and Latin American Business Schools. Her areas of interests are health management, managing innovation and entrepreneurship in health care & education, European health and research policies and global health.

She served as senior expert at the World Bank LAC Region (2001-2) and in different assignments for the European Commission (health research and policy), the European Parliament and the ECDC, such as rapporteur on the Role of Universities in Regional Development (2013), the Innovative Medicine Initiative (IMI). She assumed scientific coordination of a series of H2020/ FP7 projects (since 2004), i.e. Europe 4 Patients, Project Integrate; A leading role in EIT Health (since 2015) particularly in the Public Affairs Group and the CAMPUS activities: such as the Women Entrepreneurship Health (WEHealth) initiative and the collaboration with the Global Educators Network for Health Care Innovation and Entrepreneurship (GENiE). Publications include articles, cases and teaching material and a recent study on the Hospital of the Future (IESE, 2016)



Naureen A.
Shaikh

MD, swMBA, FAAFP,
NAPCRGF;
CEO, MyType

Dr. Naureen Shaikh, transitioned from treating and curing disease 1 patient at a time as a family doctor; to 60,000 people at a time in her Bay Area public health work; to 250,000 people at a time with direct **healthcare, disaster response and novel systems approaches in the America's, SubSaharan Africa and Asia**; to 2 Million people through the Diffusion free health education portal in 10 languages and >65 **countries under MobileMedicalTeam.org's (MMTI), partnership with Facebook / Internet.org**. Dr Shaikh founded at MMTI with target populations over 10 million, and a 21st Century health- fintech model for financially and politically autonomous global healthcare, using big data controlled by the patient. Dr. Shaikh is a global leader in human centered design and a regular participant at innovation, technology and global health forums.



M. Russell
Williams

CEO,
Fundamental Solutions
Corporation

Russell Williams, J.D. has 25 years of executive and entrepreneurial experience in both the business and legal arena. He has worked for several large corporations, including Wal-Mart and Blockbuster, where as a Corporate Operations Turnaround Specialist he was able to make profits from various money-losing divisions in under 12 months. Russell has also been involved with several startup operations, including an IPO and an exit, and is uniquely qualified to handle the complexities involved in product development and operations. Mr. Williams is one of the founders and the CEO of FSC. FSC was created to provide innovative solutions to the complexities of healthcare, food safety and security.



Tatsuya Kondo

Chief Executive,
Pharmaceuticals and
Medical Devices Agency
(PMDA)

Dr. Tatsuya Kondo is Chief Executive of Pharmaceuticals and Medical Devices Agency (PMDA). He has been in this position since 2008. He is responsible for all the operations of PMDA, that is relief for adverse health effects of drugs, drug/medical devices reviews, and post-marketing safety measures and so on. He is also major player of ICMRA as meeting comprised of top of the Drug Regulatory Agencies.

Before taking the current position, he spent most of his career as a neurosurgeon after he graduated from Medical Department of the University of Tokyo in 1968. He worked at various medical institutions, including the First National Hospital and Faculty of Medicine, the University of Tokyo.

He also has wide-ranging experience overseas, such as fellowship in Max-Planck Institute in Germany for biological research on brain tumor in 1977, and visiting staff surgeon in China-Japan Friendship Hospital in Beijing in 1987 to establish its Department of Neurosurgery under JICA project.

Currently, he is also serving as the Advisor on Health and Medical Strategy for Cabinet Secretariat of Japanese Government, and as the Vice President of Medical Excellence JAPAN, a general incorporated association.



James S. Sergi
President,
CSSi LifeSciences

Prior to founding **CSSi LifeSciences™**, Jim has held various positions in academic oncology and cancer research before co-founding ProED, a healthcare services and drug development company. CSSi and ProED have been responsible for over 70 successful FDA NDA/BLA and EMA applications and defenses for various drugs, biologics and diagnostic tests, including over 250 medical devices 510(K) submissions.

Jim has helped clients create a strategic pathway from discovery to commercialization that resulted in a reduction of development time, costs and resources, which was seen in his role played in the commercial **success of over 400 drugs and biologics**. **Jim's academic and medical experience includes Director for the** Department of Experimental Therapeutics at the Cleveland Clinic Cancer Center, Associate Professor of Medical-Surgical Nursing at the Case Western Reserve University and Lecturer for Oncology at Cleveland State University. He has authored over 75 scientific and medical publications.

Jim serves as an advisor to numerous private equity and venture backed investment firms. Jim is also a scientific reviewer for the NIH SBIR/STTR Commercial Readiness Program and as a mentor to the NIH/NHLBI and the NIH Larta FeedForward programs. Jim serves as a member of the Global Center for Health Innovation and the NorCoBio Task Forces. In addition, Jim is a frequent speaker focusing on accelerating commercial readiness and value through strategic regulatory and clinical planning.



William H. Dow
Interim Dean,
School of Public Health,
University of California,
Berkeley

William H. Dow is Interim Dean and the Kaiser Permanente Professor of Health Policy and Management at the University of California—**Berkeley's School of Public Health**. He also serves as Director of the UC-Berkeley Center on the Economics and Demography of Aging (CEDA.berkeley.edu). His academic research elucidates economic determinants of healthy aging in the U.S. and other OECD countries as well as in emerging economies. Honors include the Kenneth J. Arrow Award given by the International Health Economics Association. Dow has worked with both Democratic and Republican groups on health sector reform proposals at the federal, state and local levels. He is also a research associate at the National Bureau of Economic Research, and previously served as senior economist for health at the White House Council of Economic Advisers. Dow holds a PhD in economics from Yale University.



John Haaga
Director,
Division of Behavioral and
Social Research,
National Institute on Aging

John Haaga is Director of the Division of Behavioral and Social Research in the National Institute on Aging (part of the US National Institutes of Health). **He leads NIA's extramural program funding research in** economics, demography, epidemiology, cognitive science, behavioral and population genetics, behavioral medicine, and health services research related to aging. Division staff manage over 700 grants totaling \$340m each year. This program includes major data collection and dissemination in the United States and cross-national comparative research on global health and aging. He served as Deputy Director of this division from 2004 to 2015.

Before joining NIA, he was Director of Domestic Programs and Director of the Center for Public Information on Population Research at the Population Reference Bureau, a nonprofit research organization. During 1994 -97 he was staff director for the Committee on Population of the National Academy of Sciences. He has served as President of the Association of Population Centers, and as an elected Board member, Finance Committee Chair, and Secretary-Treasurer of the Population Association of America. From 1991 to 1994 he directed extension research in family planning and maternal and child health at the International Centre for Diarrhoeal Disease Research, Bangladesh. During the 1980s, Dr. Haaga was a Policy Analyst in the health program at RAND and a Research Associate for the Cornell University International Nutrition program. His PhD in Policy Analysis was awarded by the RAND Graduate School, and he has a BA in Modern History (with first-class honours) from Oxford University and an MA in International Relations from Johns Hopkins University. He has taught courses at the University of Maryland School of Public Policy, Georgetown University, and the Defense Intelligence College.



Larissa Lapteva
Associate Director,
DCEPT/OTAT Center for
Biologics Evaluation and
Research,
FDA

Dr. Larissa Lapteva is the Associate Director for Clinical and Nonclinical Regulation in the Division of Clinical Evaluation, Pharmacology, and Toxicology, in the Office of Tissues and Advanced Therapies in the Center for Biologics Evaluation and Research at FDA. Dr. Lapteva is a physician with long-standing experience in clinical research with novel drugs and biological products. Prior to her work at FDA, Dr. Lapteva served as a lead clinical investigator in clinical trials conducted at the National Institutes of Health (NIH). Since joining FDA in 2006, Dr. Lapteva has held review and leadership positions in the Office of New Drugs and Office of Generic Drugs in the Center for Drug Evaluation and Research and in the Center for Biologics Evaluation and Research and provided scientific and regulatory advice for clinical development programs with investigational products across different therapeutic areas. Dr. Lapteva is a practicing clinician and serves as faculty at the National Institute of Arthritis, Musculoskeletal, and Skin Diseases, NIH, advancing the teaching mission of the Institute for the next generation of physician-scientists. Dr. Lapteva received her degrees of Master of Health Sciences from Duke University and Master of Business Administration from R.H. Smith School of Business.



Yasuyuki Sahara
Councilor,
Minister's Secretariat,
Ministry of Health,
Labour and Welfare, Japan

Dr. Sahara has been Councilor at the Minister's Secretariat since 2017. He started his carrier as a pediatrician at Kanagawa Children's Medical Center and then joint the ministry as a medical officer. He served in various positions within the ministry, including Directors for the Research and Development Division, Health for Aging Division and Health Science Division, and also worked at WHO HQs as Senior Advisor on Non-Communicable Diseases. Currently, he oversees the Ministry's policy on science, technology and innovation.

He graduated Kanazawa University School of Medicine and Harvard University School of Public Health.

Speakers: Friday, November 16, 2018 (PM Session)



John Selig
Co-Founder
& Managing Partner,
WaveEdge Capital;
President,
WaveEdge Health

John advises healthcare and life sciences companies on M&A, licensing and financial strategy. He also **speaks frequently on topics in valuation, deal term benchmarking, and strategy, including for BIO's Executive Management Training course and for Stanford Medical School's Entrepreneurship Program.**

WaveEdge Capital is a healthcare merchant bank advising companies across the healthcare space. John is also creating a new healthcare company, WaveEdge Health, to provide the tools and insights necessary for primary care physicians to remain independent and transition their Medicare patients to value-based care.

Prior to forming WaveEdge, John was a Managing Director at Woodside Capital Partners, a boutique investment bank and co-led the Healthcare Group. For the prior 12 years, he advised both Fortune 100 and VC-backed healthcare companies on transaction strategy and valuation at Strategic Decisions Group (SDG), a global management consulting firm, and Keelin Reeds Partners, a life sciences and healthcare management consulting firm. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to provide ongoing support during deal negotiations. Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP where he focused on M&A and corporate finance.

John holds a JD from Stanford Law School, where he was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa. (FINRA 24, 63, 79)



Tina Ivovic
Global Senior Director of Field Reimbursement and Health Care Economics, Abbott

Tina Ivovic is an expert in Medical Device Reimbursement with a focus on Medicare and Commercial payer policy development, administrative code creation, and payment optimization, and has spent her career not only creating reimbursement structures, but implementing reimbursement best practices at hospitals to help them maintain financial viability. After spending nearly 12 years with Thoratec Corporation, she moved over to St. Jude Medical when Thoratec was acquired, and then to Abbott when St. Jude Medical was acquired, and has been the Global Senior Director of Field Reimbursement and Health Care Economics and the Therapy Leader for Heart Failure for the past 2 and a half years. In addition to her abilities in the reimbursement arena, she also is a thought leader for the changing health care landscape, concentrating on the Affordable Care Act and the move to value-based health care delivery. She has given dozens of main-stage international and national presentations on these topics, as well as Medicare policy and reimbursement structures.

Prior to joining Abbott, Tina spent 3 years working as Manager of Strategic Policy Services at Covance Health Economics and Outcomes Services where she advised multiple pharmaceutical company and device manufacturer clients. Just prior to Covance, she worked for the Mayo Clinic in Jacksonville, Florida for 3 years, directing the coding, training, and compliance staff for both the clinic and hospital. Before that, she worked for the George Washington University Medical Faculty Associates, Division of Primary Care, where she advised the 60-physician group on regulatory changes, coding practice, and compliance. Additionally, she has worked as a project manager for Cyborg, Inc., a start-up biomedical device company, and as a practice administrator for a neurological surgery group. Ms. Ivovic received a B.A. in both Psychology and Philosophy from Mount Holyoke College. She lives outside of Annapolis, Maryland.



Adrian Mckemey
Senior Vice President & Managing Director, IQVIA

Current Responsibility: Adrian heads Global R&D Strategy Solutions in IQVIA Consulting.

Profile overview:

- Adrian joined QuintilesIMS in 2008 and is a Senior Vice President based in the New York City office
- Prior to QuintilesIMS Adrian spent 8 years in the Healthcare practice in BCG New York
- Adrian was a professor of Computer Engineering at Brunel University, London and Stanford, CA

Areas of expertise:

- Clinical transformation
- Regenerative medicine
- Virtual pharma

Education:

- PhD in High Energy Particle Physics, London University and CERN, Geneva
- Sc. in Physics (First Class), London University



Kazumi Nishikawa
Director,
Healthcare Industries Division,
Commerce and Service Industry Policy Group,
METI, Japan

Current Position:

Director, Healthcare Industries Division, Commerce and Service Industry Policy Group, METI

Previous Positions:

June 2016 – July 2017: Director for Trade Strategy, Trade Policy Bureau, **Director, Global Economic Policy Unit, Minister's Secretariat** Ministry of Economy Trade and Industry (METI), Government of Japan

July 2013 – June 2016: Executive Director, Japan External Trade Organization (JETRO) Singapore
Special Advisor to the Minister, METI

July 2012 – July 2013: Director for Policy Planning (Growth Strategy) Economic and Industrial Policy Bureau, METI

December 2009 – July 2012: Principal Deputy Director **Policy Planning and Coordination Division, Minister's Secretariat, METI**

July 2008 – December 2009: Principal Deputy Director Small and Medium Size Enterprises Finance Division, METI

July 2006 – July 2008: Deputy Director Multilateral Trade System Department, METI

July 2004 – July 2006: Deputy Director Defense Policy Division, Japan Defense Agency (Ministry of Defense)

Born: August 8, 1973

Education: BA, Faculty of Law, University of Tokyo, 1996

LLM, Northwestern University School of Law, 2003

LLM for International Study, Georgetown University Law Center, 2004

Attorney at Law, NY State, USA



Toshio Fujimoto
General Manager,
Shonan Health
Innovation Park

Toshio Fujimoto, MD, MBA, joined as the General Manager of Takeda Pharmaceutical Company Ltd.'s Health Innovation Park in Shonan in December, 2017.

“Shonan Health Innovation Park (iPark)” was officially launched in April, 2018 under his operation. In this role as the General Manager of iPark, Dr. Fujimoto provides strategic leadership and oversight for all key iPark activities, including: development and execution of business and financial plans, coordination of site operations and services, tenant recruitment and management, and marketing and public relations activities.

Dr. Fujimoto received his MD from Kyoto University and his MBA from Kobe University. He began his clinical practice as a Resident at the Department of Thoracic Surgery at Kyoto University Hospital. After completing several rotations at local area hospitals, he took a position in Germany as an Assistant Surgeon with the Thoracic Surgery Department at Ruhrlandklinik Hospital, and later moved to the U.S. to serve as Clinical Fellow, General Thoracic Surgery at the Mayo Clinic.

He experienced over 10 years.

Dr. Fujimoto is one of the most successful R&D/MD/MBA executives in Eli Lilly with sufficient clinical experience, excellent leadership traits and strong business acumen. He has been identified as global hi-potential talent in this company.

- 2017- Takeda Pharmaceutical Company, Shonan Health Innovation Park-General Manager
- 2006 –2017 Eli Lilly & Company(2015 –Vice President, Medicine Development Unit Japan)
- 2005 –2006 Shizuoka City Hospital-Consultant, Thoracic Surgery
- 2004 –2005 Mayo Clinic, Rochester-Clinical Fellow, General Thoracic Surgery, USA
- 2003 –2004 University Hospital of Freiburg, Assistant Surgeon, Thoracic Surgery, Germany
- 2001 –2003 Kyoto Katsura Hospital-Consultant, Respiratory Disease Centre
- 1999 –2001 Ruhrlandklinik-Assistant Surgeon, Thoracic Surgery, Germany
- 1994 –1999 Kyoto University Hospital, Thoracic Surgery (residency training in the affiliated hospitals at Kyoto Katsura Hospital and Fukui Red Cross Hospital)



Rajesh Grover
Adjunct Professor,
J. Craig Venter
Institute

Dr. Grover is a Scientist Entrepreneur and Innovator. He is an Adjunct Professor in the Synthetic Biology and Bio-energy Group at J Craig Venter Institute, La Jolla, California and Adjunct Assistant Professor in the Department of Immunology and Microbiology at The Scripps Research Institute (TSRI), La Jolla, California. He was a faculty at TSRI in the area of Immunology, Cell and Molecular biology. He is a board of director for the American College of Nutrition, one of the top science based nutrition association in USA. His work is focused on **understanding nature’s evolutionary solutions to biological challenges, so-called “phenotypic innovations,”** and applying this knowledge to solve biomedical problems. His most recent work is focused on developing revolutionary cell reprogramming technologies focused on age renewal phenotype, to turn back the clock. His research work has been published in top scientific journals such as Science and Proceeding of National Academy of Sciences and has many patents to his credits. His work has been featured on PBS, DER SPIEGEL Magazine, Journal of American Medical Association (JAMA), Nature Reviews, American Journal of Transplantation, San Diego Union Tribune and various news outlets around the world. He is a featured expert on TV shows and community public speaking platforms geared towards communicating Biomedicine for public engagement. He is a co-founder of a company focused on anti-Aging along with Nobel Prize winner Dr. Roger Kornberg. He is passionate about the intersection of science, medicine and technology with business. He believes in entrepreneurial solutions to global problems faced by humanity. He is a former leader and advisory board member of the University of California San Diego (UCSD) Entrepreneur Challenge, a business plan competition at UCSD, and on campus incubator BASEMENT, where his major achievements includes, raising money for the E. Challenge through corporate sponsorships, recruiting teams, due diligence of the competing teams, organize judging, marketing, branding and organizing educational events. If one has an idea or innovation, diving into entrepreneurship can appear confusing and intimidating, as there are many unknowns. To better communicate these risks to the young students and innovators, he co-directed and co-produced a **documentary film name “Risking Aspirations,” which explores people’s passions that drive them to face the challenges of entrepreneurship, and to succeed.** Rajesh is a great believer of entrepreneurship as captured in the quote. **“A breakthrough today was a crazy idea yesterday”.**



Karoly Nikolich
Chief Executive Officer and
Chairman of the Board of
Directors, Alkahest

Karoly Nikolich is Chairman of the Board of Directors and Chief Executive Officer of Alkahest. During the **1980s, he led Genentech’s entry into neuroscience and led and participated in the development of numerous protein therapeutics.** He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has served on the boards and scientific advisory boards at a number of neurotherapeutics and biotech companies, as well as investment funds. Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as postdoctoral fellow at Tulane University and UCSF before joining Genentech. He has been Consulting Professor in the Department of Psychiatry at Stanford University Medical School.



Dale Bredeesen
Professor, UCLA;
Founding President,
Buck Institute

Dr. Bredeesen is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer's disease. He graduated from Caltech, then earned his MD from Duke University Medical Center in Durham, NC. He served as Chief Resident in Neurology at the University of California, San Francisco (UCSF) before joining Nobel laureate Stanley Prusiner's laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA and the University of California, San Diego. Dr. Bredeesen directed the Program on Aging at the Burnham Institute before coming to the Buck Institute in 1998 as its founding President and CEO.

The uniform failure of recent drug trials in Alzheimer's disease has highlighted the critical need for a more accurate understanding of the fundamental nature of Alzheimer's disease. Dr. Bredeesen's research has led to new insight that explains the erosion of memory seen in Alzheimer's disease, and has opened the door to a new therapeutic approach. He has found evidence that Alzheimer's disease stems from an imbalance in nerve cell signaling: in the normal brain, specific signals foster nerve connections and memory making, while balancing signals support memory breaking, allowing irrelevant information to be forgotten. But in Alzheimer's disease, the balance of these opposing signals is disturbed, nerve connections are suppressed, and memories are lost. This model is contrary to popular dogma that Alzheimer's is a disease of toxicity, caused by the accumulation of sticky plaques in the brain. Bredeesen believes the amyloid beta peptide, the source of the plaques, has a normal function in the brain — promoting signals that allow some of the nerve connections to lapse. Thus the increase in the peptide that occurs in Alzheimer's disease shifts the memory-making vs. memory-breaking balance in favor of memory loss. This work has led to the identification of several new therapeutic candidates that are currently in pre-clinical trials.

Dr. Bredeesen's novel insights into the fundamental nature of Alzheimer's disease recently attracted an investment of \$3.5 million toward a \$10 million goal for initial clinical trials of these new therapeutics. This generous support came from the private venture capitalist Douglas Rosenberg, who is helping to fund the Alzheimer's Drug Discovery Network, centered at the Buck Institute. The unit is screening drug candidates to find those that can preserve a healthy balance in the signaling pathways that support memory. Dr. Bredeesen's work on nerve cell signaling is also the focus of a collaboration between the Buck Institute and BioMarin Pharmaceuticals, Inc., which is seeking treatments for a rare form of Alzheimer's disease, early onset Familial Alzheimer's Disease (eFAD), which may develop in people as young as 30 years of age.



Jonathan Norris
Managing Director,
Life Science & Healthcare
Practice,
Silicon Valley Bank

Jonathan Norris is a managing director of sales origination for Silicon Valley Bank. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many life science and healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations.

In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than sixteen years of banking experience working with healthcare companies and venture capital firms.

Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.



Elona Baum
Managing Director,
DEFTA Partners

Elona Baum is a Managing Director of DEFTA Partners and heads the investment function for its healthcare technologies fund. The fund focuses on early stage investments in innovative therapeutic and digital health technologies. Ms. Baum's career spans more than 20 years in drug development, initially at Genentech and then at the California Institute for Regenerative Medicine (CIRM). She has held leadership roles in business development, legal and regulatory. In this capacity she oversaw \$1 billion of investment in regenerative medicine research and clinical programs, the creation of a \$40M induced pluripotent stem cell bank and a re-vamping of intellectual property regulations governing CIRM grants. At Genentech Ms. Baum managed legal matters relating to Raptiva and the company's Spanish subsidiary while also engaging in matters of regulatory policy and strategy. Ms. Baum currently serves as a Director on the board of Endogena and the Cancer Prevention Institute of California.



Laura Deming
Founder,
Longevity Fund

Since I was a kid, I've been fascinated by the idea that longevity is a mechanism we can manipulate. I grew up in New Zealand. When I was 12, I moved to the US to take graduate coursework at UCSF before studying at MIT. I've worked in the Kenyon, Guarente, Weiss and Firestein labs on a number of topics, including aging and synthetic biology. In 2011, I started Longevity Fund, the first VC firm dedicated to funding high-potential longevity companies. So far, we've raised \$26M and have backed Unity Biotechnology, Precision Biosciences, Metacrine, Navitor, and Alexo Therapeutics.



Karl Handelsman
Director of Investments,
Roche Venture Fund

Karl Handelsman is an early stage biotech venture capitalist that has invested in over three dozen companies. Karl specializes in moving early academic insights into startup companies that can translate them into important clinical candidates. There has never been a larger pool of exciting scientific discoveries with great promise to create breakthroughs in human health and even consumer products. Yet, picking out the most important innovations and matching them with the appropriate talent and resources remains a challenge.



Chris Haskell
Ph.D.
Vice President & Head of the
West Coast Innovation
Center,
Bayer

Dr. Chris Haskell leads Bayer's West Coast Innovation Center, located in the Mission Bay neighborhood of San Francisco, Calif. The West Coast Innovation Center supports Bayer's Drug Discovery activities by developing and managing partnerships with U.S. academic research institutions and life science companies. Haskell is also responsible for cultivating life science startups within the CoLaborator, a biotech incubator space adjacent to the West Coast Innovation Center. The CoLaborator, which houses a number of startup life science firms, fosters collaboration between Bayer and emerging innovators.

Haskell is also board chair emeritus and current board member of the California Life Science Institute, the San Francisco Bay Area industry trade organization dedicated to fostering entrepreneurship, science education and workforce development in the region.

After his graduate work at the University of California, Davis and a postdoctoral fellowship at The Gladstone Institute in San Francisco, Haskell joined the Immunology group at Berlex Biosciences. Since joining Bayer in 2007, Haskell has served in various scientific leadership roles, including the Acting Head of Applied Research, the unit responsible for hemostasis research and drug development. In late **2009, Haskell was named head of Bayer's Science Hub. In 2017, he assumed oversight for the West Coast Innovation Center.**




Mike Suiters
Vice President,
Sandbox Industries

Mike is a Vice President at Sandbox Industries.

He serves as a Board Member of Wider Circle. He helps manage the Fund's investments in AbleTo, BehaveCare, high, Lumiata, and Oncology Analytics. Prior to joining Sandbox, Mike spent three years at Evolent Health helping it grow from Series A to IPO. Mike started his career at Deloitte Consulting, where he focused on the impacts of healthcare reform and the ACA on the US healthcare system.

Mike holds a BA from Davidson College and an MBA from the University of Pennsylvania's Wharton School.



Julie Friedman
Steele
CEO,
World Future Society

Julie is the CEO and the driving force, behind the World Future Society, the most influential international authority for the past 50 years in future thinking. She is also on the Board of Advisors of the United Nations Women for Peace and the Managing Director in the Friedman Family Office. The Friedman family **co-invests in the future through the World Future Society with it's for purpose driven vehicles.** Friedman Properties owns and manages fifty buildings in the city of Chicago (containing over fifty **restaurants) which accounts for some of the city's most eye-catching historical properties.**

As a polymath, autodidact and a working background in entrepreneurship, AI & technology, entertainment, science, structured finance and real estate, Julie is working to realize the vision that utilizing a futurist mindset will change our societal narrative. She is passionate about emerging knowledge and accelerating its adoption to make complex technology and scientific discoveries accessible to all. Julie thrives at the cutting edge of disruption and empathy.

Julie has garnered national and international media attention appearing in over 20 countries in print, radio, and television including The Today Show, Al Jazeera, Vanity Fair Italy, Time Magazine, and a profile in Entrepreneur Magazine. She has also been named by The Chicago Tribune as a top 100 Innovator in the City.

As a social entrepreneur and producer Julie created The 3D Printer Experience (3DPX), built an International MPEG standard to make all TV and Film video content searchable and indexable on the internet and produced and directed the Genesis Award winning documentary, Best Friend Forgotten starring actor David Duchovny.

Julie studied biochemistry and molecular biology at Boston University, Music Synthesis at the famed Berklee College of Music, and Artificial Intelligence through Stanford University. With a background in stand-up comedy, Julie brings a fresh and passionate approach to her leadership, advisory roles and appearances.



Regis B. Kelly
Director,
QB3

Dr. Regis B. Kelly is the Director of QB3, one of the four California Institutes for Science and Innovation. The QB3 innovation team converts discoveries into practical benefits for society. As Director, Dr. Kelly helped launch two QB3-associated companies, QB3@953, a Life Sciences Startup incubator and Mission Bay Capital, a venture fund. As a result of his experiences, Dr. Kelly was seconded as Senior Advisor on Innovation and Entrepreneurship to the President of the University, Janet Napolitano in 2014 and 2015.

Prior to joining QB3 in 2004, Regis Kelly served as executive vice-chancellor at UCSF and Chairman of the Department of Biochemistry and Biophysics. He holds the inaugural Byers Family Distinguished Professorship. His academic research was in the field of molecular and cellular neurobiology. His training was at Harvard, Stanford, Caltech and the University of Edinburgh. He has served on many national and international boards. In 2014 he was appointed an officer of the Order of the British Empire (OBE) for services to science, innovation, and global health.



Warren Browner
MD, MPH;
CEO,
California Pacific Medical
Center (CPMC)

Warren Browner has been with Sutter Health CPMC since 2000. He joined the affiliate as the Vice-President, Academic Affairs and Scientific Director, CPMC Research Institute. In 2009 he assumed the position of CEO of California Pacific Medical Center (CPMC). He is also a board-certified internist; Clinical Professor of Medicine, Geisel School of Medicine at Dartmouth College; and, Professor (adjunct) of Epidemiology & Biostatistics at the University of California, San Francisco (UCSF).

Prior to joining CPMC, Dr Browner was a full-time faculty member at UCSF for 15 years, serving as Chief of General Internal Medicine and Acting Chief of the Medical Service at the San Francisco VA Medical Center.

He has served as Executive Editor of the American Journal of Medicine for seven years. He has been a member of Federal panels for the National Institutes of Health, the Department of Veterans Affairs, and the Food and Drug Administration. He teaches courses in clinical research design and on publishing clinical research at CPMC and at UCSF; in addition, he continues to teach seminars on both topics at various national meetings.

He also currently volunteers to serve as Immediate Past Chair, Board of Directors of the Jewish Community Center of San Francisco; Board member of the Hospital Quality Institute, California Hospital Association (CHA); and Chair, Quality Committee of the CHA.

Dr Browner earned an A.B. from Harvard College; an M.D. from UCSF; a Master's degree in Public Health (M.P.H.) in Epidemiology from UC Berkeley; and he completed a residency in internal medicine and a fellowship in clinical epidemiology at UCSF.



Karoly Nikolich
Chief Executive Officer and
Chairman of the Board of
Directors, Alkahest

Karoly Nikolich is Chairman of the Board of Directors and Chief Executive Officer of Alkahest. During **the 1980s, he led Genentech's entry into neuroscience and led and participated in the development of numerous protein therapeutics.** He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has served on the boards and scientific advisory boards at a number of neurotherapeutics and biotech companies, as well as investment funds. Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as postdoctoral fellow at Tulane University and UCSF before joining Genentech. He has been Consulting Professor in the Department of Psychiatry at Stanford University Medical School.



Richard J. Roberts
Nobel Laureate;
CSO, New England BioLabs

Dr. Richard J. Roberts is the Chief Scientific Officer at New England BioLabs, Beverly, Massachusetts. He received a Ph.D. in Organic Chemistry in 1968 from Sheffield University and then moved as a postdoctoral fellow to Harvard. From 1972 to 1992, he worked at Cold Spring Harbor Laboratory, eventually becoming Assistant Director for Research under Dr. J.D. Watson. He began work on the newly discovered Type II restriction enzymes in 1972 and these enzymes have been a major research theme. Studies of transcription in Adenovirus-2 led to the discovery of split genes and mRNA splicing in 1977, for which he received the Nobel Prize in Medicine in 1993. During the sequencing of the Adenovirus-2 genome computational tools became essential and his laboratory pioneered the application of computers in this area. DNA methyltransferases, as components of restriction-modification systems are also of active interest and the first crystal structures for the HhaI methyltransferase led to the discovery of base flipping. Bioinformatic studies of microbial genomes to find new restriction systems are a major research focus as is the elucidation of DNA methyltransferase recognition sequences using SMRT sequencing and a new approach to m5C containing recognition sequences.



George Hara
 Ambassador;
 Chairman of the Board, Alliance Forum Foundation; Group Chairman & CEO, DEFTA Partners

Chairman of the Board, Alliance Forum Foundation
 Group Chairman & CEO, DEFTA PARTNERS
 Special Advisor to the Cabinet Office of the Prime Minister of Japan
 Professor (by courtesy), Graduate School of Medicine, Osaka University
 International Council Member, Salk Institute for Biological Studies

George Hara is an archaeologist and successful entrepreneur. While he was a graduate student at Stanford University in 1981, George founded a successful startup developing fiber optics display systems. He then established DEFTA Partners, under which he has funded and led many early-stage technology companies in the US, Europe and Israel to success, including the first gene therapy company Viagene, the first antisense therapy company Isis Pharmaceuticals, and the first bioinformatics company Arris Pharmaceuticals.

George’s public service record includes board directors of San Francisco University, Zoo, and Opera where he helped revitalize these organizations, and advisors to heads of states, governments, and international organizations. George also serves as Special Advisor to the Cabinet Office of the Prime Minister of Japan, Global Agenda and Meta Council Member of the World Economic Forum, and Chairman of the Alliance Forum Foundation, a 501(c)3 organization in a Special Consultative Status with the UN ECOSOC that conducts many initiatives in the areas of anti-malnutrition, microfinance, new industry creation, and Public Interest Capitalism. In Yokohama, Japan, George established the Hara Model Railway Museum, which he dedicates to his late father Nobutaro whose lifelong hobby was to build and collect models of trains in the world.

In the Japanese government, George has held roles of Senior Advisor to the Minister of Finance from 2005 to 2009, Deputy Chairman of the Expert Panel of the Council on Economic and Fiscal Policy, the **Prime Minister’s Special Commissioner on the Government Tax Panel, a Member of the Industrial Structure Council** of the Ministry of Economy, Trade and Industry, and a Member of the ICT council of the Minister for Internal Affairs and Communications. Under his vision of Public Interest Capitalism and through these roles, George works to build a framework to commercialize and industrialize new technologies and to **rebuild the country’s fiscal health while reducing the tax rates and increasing tax revenues at the same time.**

Master of Ceremonies



Kyoko Watanabe
 Director,
 Alliance Forum Foundation;
 Managing Director,
 DEFTA Partners

Kyoko is the Managing Director of DEFTA Partners which is an early-stage venture capital firm investing in IT and healthcare technology companies in the US, Japan and Israel. With over 20 years of experience in the venture capital industry, she oversees the operation of funds and has worked closely with over 50 early stage **companies in DEFTA’s portfolio. Kyoko advises and assists many portfolios with their strategies to expand** into the Japanese market.

She also serves on the Board of Directors of the San Francisco-Osaka sister city association and the Alliance Forum Foundation, a non-profit to harness new technologies and support innovative initiatives. She received a BA from Seishin University and MBA from University of San Francisco.



DEFTA is launching tomorrow's healthcare today with a vision to enable every person to lead a healthy life until his/her last moment through investing in innovative companies and entrepreneurs in digital health, gene & cell therapy, regenerative medicine, point-of-care diagnostics, personalized healthcare, and enabling technologies.



Healthcare Focus

Today, DEFTA Partners foresees new opportunities in the integration of technologies in the IT, biotechnology, pharmaceutical, and other healthcare fields. With a goal to extend people's healthspan, we are investing in companies developing advanced therapeutics, health IT, and enabling technologies.



IT Focus

In the late 1990s, DEFTA Partners predicted that the fundamental structure of information technology would shift from a computation-centric model to what we call the pervasive ubiquitous communications (PUC) model. Our PUC vision has paved the way for successes of technology companies in fields like embedded devices, digital TV, and online security.




Global Focus

Since the 1980s, DEFTA Partners has invested in more than 100 companies in the U.S., U.K., Israel, Bangladesh, and Japan. We bring hands-on global expertise to our portfolio companies, enabling them to scale up internationally. Sustainable growth in the developing world is also our goal. In Bangladesh, for example, we work with BRAC, the world's largest NGO, in establishing and operating a joint venture bracNet, an internet service provider.

DEFTA Healthcare Technologies: Portfolio







SHARED OFFICE

A shared office in [Nihonbashi, Tokyo](#), a gathering spot for the latest knowledge and information in the life sciences.

Nihonbashi is in the heart of Tokyo, an attractive urban environment with an abundance of businesses and hotels. This town is also garnering ample attention as a base for the life sciences. Within walking distance of Tokyo Station and accessible by multiple modes of transportation, this location greatly expands business potential.

- Membership of LINK-J is required to use the shared office.





Shared office usage charges			
Open desk	30,000–35,000 yen	Personal booth [1–5 pers.]	70,000–290,000 yen

■ Inquiries about moving into the shared office: [Nihonbashi Life Science HUB]

Tel: +81-3-6214-3086

9:00~21:00 (Japan Local Time)

■ Inquiries about LINK-J membership: [LINK-J]

Tel: +81-3-3241-4911

9:00 ~ 17:00 (Japan Local Time) / excl. Saturdays, Sundays, company holidays





Shonan Health Innovation Park

Takeda Pharmaceutical opened its Shonan Research Center to the public as The Shonan Health Innovation Park (Shonan iPark) in April 2018 to support further innovation in science. At its core, Shonan iPark’s vision is the “social implementation of innovative ideas” and its mission is to “build a life-science ecosystem that is open to the world.” It aims to provide a space where public, private, and academic sectors can collaborate to develop the innovative ideas of biotech venture companies and academia into practical applications to benefit patients.



Shonan Area

Networking Event



Beach

Gym



Exhibition

ts from overseas

iPark will seek solutions to issues facing society in the following four areas.




Merge healthcare with IT/AI technology

Accelerate next-generational research through drug development

— P L A T F O R M —

The four strategic focus areas of Shonan iPark are regenerative medicine, rare diseases, dementia, and presymptomatic diseases. To address these focus areas, Shonan iPark has not only invited corporate organizations but also collaborated with the government, local municipalities, and other science parks. Additionally, it has identified “the merging of healthcare and AI” and “the expansion of drug discovery platforms” as the fundamental drivers and is in the process of developing these drivers.

iPark offers access to state-of-the-art research facilities.



- Environment-conscious and safety-assured organic synthesis and biology laboratories (P2 certified)
- Radioisotope research laboratories
- High-tech equipment including Automated Cell Analyzer (FCM, HCS, etc.), Confocal Laser Scanning Microscopy, Realtime PCR, Imaging Analyzer, etc.

ROHTO® EYE DROPS

#1 GLOBAL OTC EYE CARE BRAND*

REDNESS + DRYNESS RELIEF



cool

Dual action cooling formula works to relieve redness & soothes dry eyes

DRY EYE RELIEF



dry-aid™

Longer lasting dry eye relief versus the leading brand†

MULTI-SYMPATOM RELIEF



ice

All-in-one solution relieves 8 common eye symptoms

MAX REDNESS RELIEF



cool max

Provides maximum strength redness relief to whiten red, irritated eyes

Cutting-Edge Innovation

Unique, clear bottle design
with mess-free, single drop dispenser

*Source Euromonitor International Limited: Consumer Health Eye Care definition, retail value share, 2016 data. †Self-reported clinical data, 2016

rohtoeyedrops.com





Proud sponsor of the
2018 World Alliance Forum
in San Francisco

“Healthcare Game Changers”

MUFG Union Bank, N.A.
A member of MUFG, a global financial group



©2018 Mitsubishi UFJ Financial Group, Inc. All rights reserved. The MUFG logo and name is a service mark of Mitsubishi UFJ Financial Group, Inc., and is used by MUFG Union Bank, N.A., with permission; Union Bank is a registered trademark and brand name of MUFG Union Bank, N.A., Member FDIC.

Innovation today, healthier tomorrows



Sumitomo Dainippon
Pharma

Gold Sponsors



I'm a Futurian.
I have come from your
not-too-far future.

While luxuries such as flying cars, robots, and AI are at the forefront of the news, the future of healthcare also holds new promise. Imagine tailor-made medications, accessing a doctor from the palm of your hand, and a new era of disease prediction and prevention. For more details, look into the future.

For a tomorrow only possible through biotechnology.

Innovation all for the patients
 CHUGAI PHARMACEUTICAL CO., LTD.
 Roche Group

INNOVATION BEYOND IMAGINATION

:DeNA

HEALTHCARE

History and Aims

The Alliance Forum Foundation holds Special Consultative Status with the United Nations ECOSOC since 2011. Founded in 1985, AFF is a 501(c)(3) nonprofit organization based in California, USA. During the 1980's, AFF played a significant role in helping to ease trade friction between Japan and the US in the field of high technology with support from the Japanese Ministry of Foreign Affairs, the Ministry of International Trade and Industry, as well as, the US Government. In 2000, recognizing the maturation of computer-centralized technology as the core industry driving the global economy, AFF established the following mission for its activities going forward:

- Deploy next generation technology to change the world.
- Support the development of new key industries through activities that nurture and commercialize promising new technologies and foster the development of human resources for a new age.
- Contribute to Japan's role as a vital actor in global development.

BOARD OF DIRECTORS

George Hara (Chairman of the Board)
Mikio Tanji (AFF PIC Research Division)
Shingo Torii (Senior Executive Vice President, Suntory Holdings, Ltd.)

Hideto Mitamura (Fmr. Ambassador to New Zealand, Samoa, Zambia & Malawi)
Seiji Yoshizawa (Alliance Forum Development Programme/AFF Operations)
Kyoko Watanabe (CFO, Director)

BOARD OF COUNCILORS

Koki Ando
CEO,
Nissin Holdings

Susumu Kaminaga
Former President,
Sumitomo Precision Products Co., Ltd

Kiyoshi Kurokawa
Professor, National Graduate
Institute For Policy Studies

Toichi Takenaka
Chairman & CEO,
Takenaka Corporation

Yuichiro Anzai
President, Japan Society for the Promotion
of Science; Professor & Former President,
Keio University

Masahiro Kan
Executive Director for Japan,
World Bank Group

Akihiro Kuroda
President, Kokuyo Co., Ltd.

Shunji Yanai
President,
International Tribunal
For the Law of the Sea

Monte Cassim
Vice-Chancellor, Ritsumeikan Trust

Yoshimitsu Kobayashi
President & CEO,
Mitsubishi Chemical Hldgs. Corporation

Isao "Steve" Matsuura
Chairman, MIK International

Kunio Yamada
Chairman and CEO,
Rohto Pharmaceuticals Co., Ltd.

Tsutomu Fuse
Former President, Yokohama City University

Hiroshi Komiyama
Chairman of the Board,
Mitsubishi Research Institute

Hideto Mitamura
Former Amb. to New Zealand,
Samoa, Zambia, Malawi

<Auditor>
Yuichi Kawarada
Professor,
Nishogakusha University

Masatoshi Ito
Founder and Honorary Chairman,
Seven & i Hldgs., Ltd.

Mika Kumahira
Representative Director
Kumahira Security Foundation

Koji Sasaki
CEO and President, Adln
Research, Inc

Seiichi Shimada
Board Director, Suruga Bank

ALLIANCE FORUM FOUNDATION



Preparations are underway to formally establish the *Global Human Resources Development Programme* which aims to dispatch talented Japanese from the private sector to staff public interest projects in developing countries.

Public Interest Capitalism (PIC) Research Division

A long-term vision rooted in the public interest is crucial to drive the development of core technologies and create new key industries. Excessive market fundamentalism and shareholder-centrism have not only created severe inequities but also hindered the development of new key industries capable of driving global development. In 1999, AFF began a series of forums to discuss and debate new capitalist mechanisms and in 2008, we established the PIC Research Division. In 2011, AFF started sponsoring a series of lectures at Tokyo University that would examine the negative effects of shareholder centrism, establish a PIC theoretical framework, and identify best practices in management that promote balanced and sustainable global development.



2010 World Alliance Forum
Tokyo Roundtable

Alliance Forum Foundation Development Programme

More than half the nations in the world are classified as developing countries. Many of these countries face problems hindering their development including poverty, hunger, malnutrition, disease, and insufficient infrastructure to deliver basic education and healthcare. The **Alliance Forum Foundation Development Programme (AFDP)** is implementing a number of activities that aim to solve these problems by harnessing the power of the private sector.

Spirulina Project (Africa)


This project seeks to combat malnutrition in Africa through the use of Spirulina, an extremely nutritious kind of microalgae. In 2010, AFDP succeeded in facilitating the import of Spirulina into Zambia for future distribution to malnourished populations. AFDP is working in cooperation with the Ministry of Health's system of malnutrition clinics and local NGO's on a two-year project aimed at distributing Spirulina free of charge to the malnourished in Zambia. In addition, AFF is working to dispatch students and young professionals to assist local populations in the safe and effective distribution of spirulina to combat malnutrition.

Microfinance Professional Courses (Bangladesh)

Microfinance is an effective development tool for assisting the poor to become financially independent. In 2009, AFDP together with BRAC University established an institute to educate aspiring microfinance professionals. Since its inception, over 70 people have graduated from the introductory course. Presently, AFDP is working to establish an in-depth master's course in microfinance.

AFF Forums and other activities

AFF annually hosts the World Alliance Forum Tokyo Roundtable and the World Alliance Forum in San Francisco as well as a variety of other international events including the AFDP-JICA Forum, a conference on development co-organized with the Japanese International Cooperation Agency (JICA). AFF also brings corporate leaders to developing countries such as Bangladesh and Zambia as part of its corporate delegation activities.



Distance Learning / Telemedicine Projects (Bangladesh and Zambia)

In 2005, AFDP's first project began with private sector partners and the world's largest NGO, BRAC, to develop a next-generation infrastructure to deliver distance learning and telemedicine in Bangladesh. This project established bracNet, a unique internet service provider deploying WiMAX technology to provide a wireless internet in Bangladesh. braNet was highlighted by the World Bank for its unique framework that uses a portion of its profits for education and healthcare initiatives in rural areas. In 2010, AFDP launched a distance learning project utilizing XVD's video compression technology that enables real-time HD distance classes at universities in Zambia. XVD will be further deployed to enhance education and healthcare in developing countries.



Lecturer (left) Sir
Fazle Hasan
Abed, Founder
and Chairperson
of BRAC.



World Alliance Forum
In Bangladesh



AFF Corporate Delegation
(Japanese Embassy in Zambia)

Diamond Sponsors



Platinum Sponsors



Gold Sponsors

Silver Sponsors



Presenters



Major Supporting Organizations

